Key Takeaways Olema shares jumped 46.5% this month on a new Pfizer collaboration for palazestrant.The phase Ib/II study will test palazestrant with Pfizer's atirmociclib in ER /HER2- MBC.Pfizer will supply atirmociclib, while Olema leads the study and keeps global rights to palazestrant.Shares of Olema Pharmaceuticals (OLMA) have rallied 46.5% so far in September after the company announced a new collaboration agreement for its lead product candidate, palazestrant, with pharma bigwig Pfizer (PFE) earlier th ...